Study using novel continuous ambulatory respiratory sensors to assess adherence among COPD patients and identify digital biomarkers preceding COPD exacerbations
COPD generates over $30B/year of healthcare costs in the US. Being able to predict exacerbations…has the potential to significantly reduce hospitalizations, making a large impact on costs as well as improving the lives of millions of people with COPD.” Jonathan Palley, CEO of Spire Health
Spire Health, the leader in long-term respiratory remote patient monitoring, announced today that it has launched a research study on COPD exacerbations, with over 100 participants already enrolled. The study is being conducted using Health Tags, Spire Health’s continuous respiratory remote monitoring sensor solution, to assess adherence among COPD patients and identify changes in physiological metrics that occur during and preceding COPD exacerbations.
Spire Health aims to use data from the trial to develop algorithms that are capable of predicting COPD exacerbations and can be implemented as part of COPD remote patient monitoring programs.